Integrated Report 2025

Our Value CreationStakeholder Engagement

At PHC Group, we seek open and constructive dialogue with the wide variety of stakeholders who contribute to our business. We actively listen to the perspectives and expectations of these stakeholder groups, including customers, employees, business partners, shareholders, local communities, government agencies, and the media. By fostering two-way communication and ensuring timely and appropriate disclosure of information, we aim to build and maintain strong, trusting relationships.
When sharing information about our business activities and initiatives, we prioritize timeliness, transparency, and accuracy. Through ongoing dialogue with our stakeholders, we stay closely attuned to their needs and expectations and incorporate those insights into our business activities, with the goal of driving sustainable growth and creating long-term corporate value.

* To view the entire image of the Stakeholder Engagement, please hold your cursor over the scroll bar below the image and move it to the left or right.

ステークホルダーエンゲージメント

Specific Initiatives

1. Co-creation with Local Communities (Collaboration with Toon City, Ehime, Japan)

Since its founding as Matsushita Kotobuki Electronics Co., Ltd. in Toon City, Ehime Prefecture, in 1969, PHC Group has been strengthening our collaboration with the city. In 2018, PHC Corporation, a subsidiary of PHC Group, signed a partnership agreement for regional cooperative projects with Toon City. In 2023, Wemex Corporation, a member of PHC Group, joined the agreement, further advancing collaborative activities in the region. In 2024, as part of Toon City’s “Toon Smart Healthcare Creation Project,” Wemex introduced the real-time telemedicine system, Teladoc HEALTH, in Shikoku. By deploying a Mobility as a Service (MaaS) vehicle equipped with Teladoc HEALTH, the project addresses local challenges such as providing online health consultations for city residents and preventive healthcare support for the elderly. PHC Group will continue to promote collaboration and co-creation with local governments and communities.

Online health consultation with a Teladoc HEALTH-equipped MaaS vehicle
Online health consultation with a Teladoc HEALTH-equipped MaaS vehicle
Media event on September 21, 2024, to celebrate the launch of the MaaS vehicle (Photo: Hideaki Takahashi, President of Wemex Corporation, on the far right)
Media event on September 21, 2024, to celebrate the launch of the MaaS vehicle (Photo: Hideaki Takahashi, President of Wemex Corporation, on the far right)

2. Joint Development Toward Social Implementation of Regenerative Medicine

In March 2025, the Biomedical Division of PHC Corporation (PHCbi) participated in the 24th Congress of the Japanese Society for Regenerative Medicine.
During the congress, PHCbi and Cyfuse Biomedical K.K., a company with proprietary Bio 3D Printing technology, co-hosted an academic luncheon seminar on “The Evolution and Future of Regenerative Medicine.” In the poster session, the companies presented new production technologies for the commercialization of 3D cell products, which are being jointly developed by PHCbi and Cyfuse.
PHCbi also exhibited some strategic products, including the LiCellGrow™ cell expansion system under development, as part of its efforts to enhance its presence in the cell and gene therapy (CGT) field. The PHCbi booth attracted significant attention from members of the media and representatives from industry associations.
Through these initiatives and others, PHC Group is contributing to the future of regenerative medicine and will continue to take on the challenge of advancing related healthcare in the years to come.

Kyoko Deguchi, President and CEO of PHC Holdings Corporation (center) and Shizuka Akieda, CEO of Cyfuse Biomedical K.K. (second from the right) at the 24th Congress of the Japanese Society for Regenerative Medicine.
Kyoko Deguchi, President and CEO of PHC Holdings Corporation (center) and Shizuka Akieda, CEO of Cyfuse Biomedical K.K. (second from the right) at the 24th Congress of the Japanese Society for Regenerative Medicine.